Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database
Abstract
Aim: Examine treatment patterns among patients with active ankylosing spondylitis (AS) treated with a TNF inhibitor (TNFi). Patients & methods: Patients with AS who initiated a TNFi between 1 January 2013, and 31 January 2015, were identified in the Optum Research Database. Outcomes included adherence, persistence, discontinuation and therapy modifications of the index TNFi during 12-month follow-up. Results: Of the 426 patients included, 40.6% persisted on the index TNFi for ≥12 months, 31.0% discontinued, 21.4% switched to a different TNFi, and 7.0% discontinued and then restarted. Of the 333 patients who persisted on their TNFi for >90 days, 44.7% received ≥1 add-on medication. Conclusion: A high proportion of patients with AS switched, discontinued or modified their TNFi therapy.
Supplementary Material
File (supplementary_material.docx)
- Download
- 110.25 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthritis. Nat. Rev. Dis. Primers 1, 15013 (2015).
2.
Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N. Engl. J. Med. 374(26), 2563–2574 (2016).
•• Provides a thorough overview of ankylosing spondylitis (AS) including the history, diagnosis and treatment.
3.
Reveille JD. Epidemiology of spondyloarthritis in North America. Am. J. Med. Sci. 341(4), 284–286 (2011).
4.
Strand V, Rao SA, Shillington AC, Cifaldi MA, McGuire M, Ruderman EM. Prevalence of axial spondyloarthritis in United States rheumatology practices: assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care. Res. (Hoboken) 65(8), 1299–1306 (2013).
5.
Curtis JR, Harrold LR, Asgari MM et al. Diagnostic prevalence of ankylosing spondylitis using computerized health care data, 1996 to 2009: underrecognition in a US health care setting. Perm. J. 20(4), 4–10 (2016).
6.
Klingberg E, Svealv BG, Tang MS, Bech-Hanssen O, Forsblad-d'Elia H, Bergfeldt L. Aortic regurgitation is common in ankylosing spondylitis: time for routine echocardiography evaluation? Am. J. Med. 128(11), 1244.e1–1250.e1 (2015).
7.
Ho HH, Yeh SJ, Tsai WP, Wang CM, Chen JY. Paroxysmal supraventricular tachycardia and Wolff-Parkinson-White syndrome in ankylosing spondylitis: a large cohort observation study and literature review. Semin. Arthritis Rheum. 42(3), 246–253 (2012).
8.
Rosenbaum JT. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin. Rheumatol. 34(6), 999–1002 (2015).
9.
Keller JJ, Hsu JL, Lin SM et al. Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study. Rheumatol. Int. 34(2), 255–263 (2014).
10.
van der Heijde D, Ramiro S, Landewe R et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 76(6), 978–991 (2017).
• Current European league against rheumatism recommendations for management and treatment of AS.
11.
Ward MM, Deodhar A, Akl EA et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care. Res. (Hoboken) 68(2), 151–166 (2016).
• Current American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for management and treatment of AS.
12.
Maxwell LJ, Zochling J, Boonen A et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst. Rev. (4), CD005468 (2015).
13.
Davis JC Jr, Van Der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48(11), 3230–3236 (2003).
14.
Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313), 1187–1193 (2002).
15.
Landewe R, Braun J, Deodhar A et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann. Rheum. Dis. 73(1), 39–47 (2014).
16.
van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54(7), 2136–2146 (2006).
17.
Baeten D, Sieper J, Braun J et al. Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373(26), 2534–2548 (2015).
18.
Inman RD, Davis JC Jr, Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, Phase III trial. Arthritis Rheum. 58(11), 3402–3412 (2008).
19.
Sepriano A, Regel A, van der Heijde D et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open (2017) (Epub aheadof print).
20.
Conti F, Ceccarelli F, Marocchi E et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5 year period. Ann. Rheum. Dis. 66(10), 1393–1397 (2007).
21.
Lie E, van der Heijde D, Uhlig T et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann. Rheum. Dis. 70(1), 157–163 (2011).
22.
Palmer JB, Li Y, Herrera V, Liao M, Ozturk Z. Treatment patterns and costs for anti-TNFα therapy in patients with ankylosing spondylitis. Rheum. Curr Res S6(007), (2015).
23.
Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv. Ther. 29(8), 664–674 (2012).
24.
Howe A, Eyck LT, Dufour R, Shah N, Harrison DJ. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database. J. Manag. Care. Spec. Pharm. 20(12), 1236–1244 (2014).
25.
Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS. A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients. Adv. Ther. 33(4), 626–642 (2016).
26.
Lyu R, Govoni M, Ding Q et al. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Rheumatol. Int. 36(1), 143–153 (2016).
27.
Martinez-Cutillas J, Alerany-Pardo C, Borras-Blasco J et al. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. Expert Rev. Pharmacoecon. Outcomes Res. 15(5), 851–858 (2015).
28.
Garrido-Cumbrera M, Hillmann O, Mahapatra R et al. Improving the management of psoriatic arthritis and axial spondyloarthritis: roundtable discussions with healthcare professionals and patients. Rheumatol. Ther. (2017) (Epub ahead of print).
•• Provides insight into treatments of axial spondyloarthritis and unmet needs from both a healthcare professional and patient perspective.
29.
Quan H, Li B, Couris CM et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 173(6), 676–682 (2011).
30.
Bayliss EA, Ellis JL, Shoup JA, Zeng C, McQuillan DB, Steiner JF. Association of patient-centered outcomes with patient-reported and ICD-9-based morbidity measures. Ann. Fam. Med. 10(2), 126–133 (2012).
31.
Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS. A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients. Adv. Ther. 33(4), 626–642 (2016).
32.
Fabbroni M, Cantarini L, Caso F et al. Drug retention rates and treatment discontinuation among anti-TNF-alpha agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm. (2014) (Epub aheadof print).
33.
Gulyas K, Bodnar N, Nagy Z et al. Real-life experience with switching TNF-alpha inhibitors in ankylosing spondylitis. Eur. J. Health. Econ. 15(Suppl. 1), S93–S100 (2014).
34.
Ciurea A, Exer P, Weber U et al. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res. Ther. 18, 71-016–0969-2 (2016).
35.
Arends S, Brouwer E, van der Veer E et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res. Ther. 13(3), R94 (2011).
36.
Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv. Ther. 29(8), 664–674 (2012).
37.
Glintborg B, Ostergaard M, Krogh NS et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann. Rheum. Dis. 72(7), 1149–1155 (2013).
38.
Wang Y, Wang H, Jiang J, Zhao D, Liu Y. Comparative efficacy and acceptability of anti-TNF-alpha therapy in ankylosing spondylitis: a mixed-treatments comparison. Cell. Physiol. Biochem. 39(5), 1679–1694 (2016).
39.
Murdaca G, Spano F, Contatore M et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin. Drug Saf. 15(1), 43–52 (2016).
Information & Authors
Information
Published In
Copyright
© 2017 Jessica A Walsh.
History
Received: 26 September 2017
Accepted: 26 October 2017
Published online: 17 November 2017
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. (2017) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2017-0076
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Berkay Aktas, Enes Azman, Hüsnü Mert Yüksel, Berilnur Erdogan, Kerem Parlar, Ceren Uc, Serdal Ugurlu, Certolizumab in Axial Spondyloarthritis: Persistence and Determinants, International Journal of Rheumatic Diseases, 10.1111/1756-185X.70331, 28, 6, (2025).
- Muhammad Umer Rashid, Amina Khurshid, Hassan Shaukat, Fahd Farooq Ashraf, Muhammad Haseeb Lodhi, Amir Naveed, Muhammad Farrukh Habib, Disease Patterns of Ankylosing Spondylitis Associated Treatment Patterns and Drug Utilization among Affected Patients, Pakistan Journal of Health Sciences, 10.54393/pjhs.v5i06.1376, (13-18), (2024).
- Divya Shridharmurthy, Kate L. Lapane, Jonggyu Baek, Anthony P. Nunes, Michael H. Weisman, Jonathan Kay, Shao‐Hsien Liu, Sex Differences in Time to Initiate Nonsteroidal Anti‐Inflammatory Drugs or Biologic Disease‐Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis, Arthritis Care & Research, 10.1002/acr.25332, 76, 8, (1149-1161), (2024).
- Haibo Li, Jingjing Liu, Xueping Ji, Interferon-alpha 1 expression indicates the disease activity and response of patients with ankylosing spondylitis to anti-TNF-α treatment, Modern Rheumatology, 10.1093/mr/road039, 34, 3, (592-598), (2023).
- Siming Chen, Toshiki Fukasawa, Akio Ikeda, Masato Takeuchi, Akihiro Shimotake, Satomi Yoshida, Koji Kawakami, Adherence to and persistence with lacosamide, perampanel, lamotrigine, and levetiracetam in adult patients with focal epilepsy in Japan: A descriptive cohort study using a claims database, Heliyon, 10.1016/j.heliyon.2023.e15017, 9, 4, (e15017), (2023).
- Yulan Hu, Bo Lou, Zhonghua Jiang, Chunchu Yu, Predictive Values of Blood Type I and Type II Interferon Production for Disease Activity and Clinical Response to TNF-α Blocking Therapy in Patients with Ankylosing Spondylitis, The Tohoku Journal of Experimental Medicine, 10.1620/tjem.2023.J033, 260, 3, (263-271), (2023).
- Alexis Ogdie, Mark Hwang, Phani Veeranki, Alexandria Portelli, Steven Sison, Jason Shafrin, Sofia Pedro, Nina Kim, Esther Yi, Kaleb Michaud, Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2022.28.9.1008, 28, 9, (1008-1020), (2022).
- Sang‐Hoon Lee, Yong‐Gil Kim, Seung‐Geun Lee, Soo Hyun Lee, Young‐Joo Kim, Ja‐Young Jeon, Joo‐Young Jo, Hyun‐Jeong Yoo, Juneyoung Lee, Tae‐Hwan Kim, Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross‐sectional observational study, International Journal of Rheumatic Diseases, 10.1111/1756-185X.14304, 25, 5, (523-531), (2022).
- Kentaro Inui, Masayo Sato, Elizabeth Esterberg, Rohan C Parikh, Shuichi Kimura, Hitoe Torisu-Itakura, Treatment practices and costs among patients with psoriatic arthritis: A Japanese hospital claims database analysis, Modern Rheumatology, 10.1080/14397595.2021.1886629, 31, 6, (1179-1191), (2021).
- Shin-Seok Lee, Tae-Hwan Kim, Won Park, Yeong-Wook Song, Chang-Hee Suh, Soo-Kyoung Kim, Dae-Hyun Yoo, Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis, Journal of Clinical Medicine, 10.3390/jcm10194568, 10, 19, (4568), (2021).